Research Reference Library · Educational Use Only

Semaglutide vs Tirzepatide vs Retatrutide: GLP-1 Agonist Comparison

Last reviewed 2025 · Focus: semaglutide vs tirzepatide vs retatrutide · Source: peer-reviewed preclinical literature

Receptor Targets

CompoundGLP-1GIPGlucagon
Semaglutide✓——
Tirzepatide✓✓—
Retatrutide✓✓✓

Weight Loss Data from Clinical Trials

Semaglutide (2.4 mg/week) produced approximately 15% body weight reduction in the STEP trials. Tirzepatide at 15 mg/week produced up to 22.5% in SURMOUNT-1. Retatrutide in Phase 2 trials produced up to 24.2% at 12 mg/week — the highest of the three, driven by the additional glucagon receptor activation increasing energy expenditure.

Half-Life Comparison

Side Effect Profile

All three share a GI side effect profile (nausea, vomiting, constipation) most pronounced during dose escalation. Retatrutide's additional glucagon activity may cause greater increases in heart rate at higher doses.

Research-grade retatrutide and semaglutide available at QSC Peptides.

Research-grade peptides with HPLC-verified COA
All compounds referenced in this guide are available at QSC Peptides (qscpeptide.com) — US domestic warehouse, fast shipping, batch-level certificates of analysis.

This page is for educational and research purposes only. All products sold by QSC are labelled for research use only and are not intended for human consumption. Nothing on this page constitutes medical advice.